Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Nov;52(11):780-4.
doi: 10.1136/ard.52.11.780.

Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone

Affiliations

Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone

L Martin et al. Ann Rheum Dis. 1993 Nov.

Abstract

Objectives: The role of autoantibodies in the investigation and management of rheumatic diseases is well recognised. The objective of this study was to determine the clinical significance of the co-occurrence of antibodies to centromere and histone in serum samples from patients investigated for systemic rheumatic diseases.

Methods: Serum samples from 1316 consecutive patients were screened for antinuclear antibodies and the clinical findings in patients with antibodies to centromere alone were compared with those with antibodies to both centromere and histone.

Results: Twenty six patients had antibodies to centromere. Fourteen patients had antibodies to centromere alone and 12 patients had antibodies to centromere and histone. Four of the 12 patients with antibodies to centromere and histone had diffuse scleroderma with severe pulmonary or vascular disease.

Conclusions: A subset of patients with scleroderma with antibodies to centromere and histone has been identified retrospectively, who have severe pulmonary or vascular disease. It will be of interest to follow up the clinical course of other patients with scleroderma who have both antibodies for the development of pulmonary or vascular disease.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. J Clin Invest. 1978 Sep;62(3):560-7 - PubMed
    1. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3734-8 - PubMed
    1. J Biol Chem. 1979 Oct 25;254(20):10514-22 - PubMed
    1. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1627-31 - PubMed
    1. Am J Med. 1980 Oct;69(4):520-6 - PubMed

Publication types